Recent research trials surrounding Retatrutide , specifically the 120mg formulation branded as ZPHC, suggest a considerable impact on weight loss and associated health conditions . Researchers anticipate that this innovative agonist , influencing both GLP-1 and GIP receptors , has the potential to offer a major breakthrough in the management of ove